Survival rates of patients with metastatic malignant melanoma.

作者: A Sandru , E Panaitescu , S Voinea , A Blidaru

DOI:

关键词:

摘要: Malignant melanoma (MM) is the cutaneous neoplasia with greatest mortality rates and one of malignancies highest potential dissemination. The prognosis patients metastatic MM grim, a 5-years survival rate between 5- 19%, dictated by location number metastases. Objective: We aimed to estimate from our study find out if metastasis' influences survival. Methods results: Between 2008 2013, 155 were diagnosed in clinic. All staged according 2009 AJCC staging system. median follow-up period was 24 months. Survival calculated using Kaplan-Meier method confidence level 95%. 40.5% developed metastases different organs, especially brain. 80.6% those died during study. overall survival, estimated for entire group who metastases, 5.3 Discussion: influence distribution on examined it noticed that there statistically significant differences risks death various groups patients, depending metastasis topography. Thus, probability patient brain twice digestive metastasis, about 7 times higher than lung (p = 0.0004) 12 risk extra-regional lymph nodes or subcutaneous 0.0000).

参考文章(14)
A. Sanki, R.A. Scolyer, J.F. Thompson, Surgery for melanoma metastases of the gastrointestinal tract: indications and results. Ejso. ,vol. 35, pp. 313- 319 ,(2009) , 10.1016/J.EJSO.2008.04.011
Matthew F. Kalady, Rebekah R. White, Jeffrey L. Johnson, Douglas S. Tyler, Hilliard F. Seigler, Thin Melanomas: Predictive Lethal Characteristics from a 30-Year Clinical Experience Annals of Surgery. ,vol. 238, pp. 528- 537 ,(2003) , 10.1097/01.SLA.0000090446.63327.40
Richard Essner, Jonathan H Lee, Leslie A Wanek, Hitoe Itakura, Donald L Morton, Contemporary Surgical Treatment of Advanced-Stage Melanoma Archives of Surgery. ,vol. 139, pp. 961- 967 ,(2004) , 10.1001/ARCHSURG.139.9.961
Shanique R. Palmer, Lori A. Erickson, Ilia Ichetovkin, Daniel J. Knauer, Svetomir N. Markovic, Circulating Serologic and Molecular Biomarkers in Malignant Melanoma Mayo Clinic Proceedings. ,vol. 86, pp. 981- 990 ,(2011) , 10.4065/MCP.2011.0287
Rebecca P. Petersen, Steven I. Hanish, John C. Haney, Charles C. Miller, William R. Burfeind, Douglas S. Tyler, Hilliard F. Seigler, Walter Wolfe, Thomas A. D’Amico, David H. Harpole, Improved survival with pulmonary metastasectomy: An analysis of 1720 patients with pulmonary metastatic melanoma The Journal of Thoracic and Cardiovascular Surgery. ,vol. 133, pp. 104- 110.e2 ,(2007) , 10.1016/J.JTCVS.2006.08.065
Nabil Wasif, Sanjay P. Bagaria, Partha Ray, Donald L. Morton, Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. Journal of Surgical Oncology. ,vol. 104, pp. 111- 115 ,(2011) , 10.1002/JSO.21903
Jaime M. Ranieri, Jeffrey D. Wagner, Stacie Wenck, Cynthia S. Johnson, John J. Coleman, The prognostic importance of sentinel lymph node biopsy in thin melanoma. Annals of Surgical Oncology. ,vol. 13, pp. 927- 932 ,(2006) , 10.1245/ASO.2006.04.023
Charles M Balch, Jeffrey E Gershenwald, Seng-jaw Soong, John F Thompson, Michael B Atkins, David R Byrd, Antonio C Buzaid, Alistair J Cochran, Daniel G Coit, Shouluan Ding, Alexander M Eggermont, Keith T Flaherty, Phyllis A Gimotty, John M Kirkwood, Kelly M McMasters, Martin C Mihm Jr, Donald L Morton, Merrick I Ross, Arthur J Sober, Vernon K Sondak, None, Final Version of 2009 AJCC Melanoma Staging and Classification Journal of Clinical Oncology. ,vol. 27, pp. 6199- 6206 ,(2009) , 10.1200/JCO.2009.23.4799
M.B. Lens, M. Dawes, Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. British Journal of Dermatology. ,vol. 150, pp. 179- 185 ,(2004) , 10.1111/J.1365-2133.2004.05708.X
Csaba Gajdos, Martin D McCarter, Debulking surgery in advanced melanoma. Expert Review of Anticancer Therapy. ,vol. 11, pp. 1703- 1712 ,(2011) , 10.1586/ERA.11.98